Novartis Ag (NVS) Capital Expenditures (2009 - 2026)

Novartis Ag (NVS) has 16 years of Capital Expenditures data on file, last reported at -$346.0 million in Q1 2026.

• Quarterly Capital Expenditures fell 36.22% year-over-year to -$346.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.6 billion (down 17.73% YoY) and the FY2025 annual result came in at $1.5 billion, up 13.32% from the prior year.
• Capital Expenditures advanced to -$346.0 million in Q1 2026 per NVS's latest filing, from -$609.0 million in the prior quarter.
• The five-year high for Capital Expenditures was -$168.0 million in Q1 2023, with the low at -$609.0 million in Q4 2025.
• Average Capital Expenditures over 5 years is -$315.4 million, with a median of -$261.0 million recorded in 2023.
• Year-over-year, Capital Expenditures jumped 37.04% in 2022 and slumped 37.44% in 2024.
• Novartis Ag's Capital Expenditures stood at -$306.0 million in 2022, then sank by 32.68% to -$406.0 million in 2023, then tumbled by 37.44% to -$558.0 million in 2024, then fell by 9.14% to -$609.0 million in 2025, then soared by 43.19% to -$346.0 million in 2026.
• Business Quant data shows NVS's Capital Expenditures at -$346.0 million in Q1 2026, -$609.0 million in Q4 2025, and -$354.0 million in Q3 2025.